ATAI vs. RCKT, ZYME, GYRE, PSTX, OCS, ADPT, CVAC, NUVB, AVXL, and ABCL
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Rocket Pharmaceuticals (RCKT), Zymeworks (ZYME), Gyre Therapeutics (GYRE), Poseida Therapeutics (PSTX), Oculis (OCS), Adaptive Biotechnologies (ADPT), CureVac (CVAC), Nuvation Bio (NUVB), Anavex Life Sciences (AVXL), and AbCellera Biologics (ABCL). These companies are all part of the "pharmaceutical products" industry.
Atai Life Sciences vs.
Rocket Pharmaceuticals (NASDAQ:RCKT) and Atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Atai Life Sciences has higher revenue and earnings than Rocket Pharmaceuticals. Rocket Pharmaceuticals is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Rocket Pharmaceuticals had 3 more articles in the media than Atai Life Sciences. MarketBeat recorded 3 mentions for Rocket Pharmaceuticals and 0 mentions for Atai Life Sciences. Rocket Pharmaceuticals' average media sentiment score of 0.23 beat Atai Life Sciences' score of 0.00 indicating that Rocket Pharmaceuticals is being referred to more favorably in the media.
Rocket Pharmaceuticals' return on equity of -62.62% beat Atai Life Sciences' return on equity.
Rocket Pharmaceuticals currently has a consensus price target of $47.27, indicating a potential upside of 358.51%. Atai Life Sciences has a consensus price target of $9.00, indicating a potential upside of 516.44%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe Atai Life Sciences is more favorable than Rocket Pharmaceuticals.
Rocket Pharmaceuticals received 60 more outperform votes than Atai Life Sciences when rated by MarketBeat users. Likewise, 73.22% of users gave Rocket Pharmaceuticals an outperform vote while only 66.33% of users gave Atai Life Sciences an outperform vote.
98.4% of Rocket Pharmaceuticals shares are held by institutional investors. Comparatively, 28.4% of Atai Life Sciences shares are held by institutional investors. 28.5% of Rocket Pharmaceuticals shares are held by company insiders. Comparatively, 31.2% of Atai Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Rocket Pharmaceuticals has a beta of 1.01, indicating that its share price is 1% more volatile than the S&P 500. Comparatively, Atai Life Sciences has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.
Summary
Atai Life Sciences beats Rocket Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATAI) was last updated on 1/21/2025 by MarketBeat.com Staff
Free ATAI Stock Alerts